XtalPi

Jian Ma, a co-founder and MIT-trained physicist, serves as CEO and sets the strategic direction. Chairman Shuhao Wen—also an MIT physics alumnus—oversees corporate governance. The third co-founder, Lipeng Lai, focuses on core algorithm development. The firm's nearly 400 PhD-level researchers drive individual program execution across the Shenzhen, Kowloon, and Atlanta labs.

XtalPi operates on a milestone-and-royalty model rather than taking equity in drug candidates. Publicly disclosed partners include Pfizer, Eli Lilly, and Johnson & Johnson (per S-1 filing, 2023). Revenue comes from upfront technology access fees, research-milestone payments when compounds advance into preclinical testing, and downstream royalties on successful candidates. The firm also earns materials-science fees from industrial collaborations with Sinopec and other chemical manufacturers.

No. XtalPi is an operating company that went public on the Hong Kong Stock Exchange in November 2023. It does not manage third-party capital or invest in portfolio companies. It deploys its own R&D budget and IPO proceeds to run drug-discovery programs, with returns tied to pharmaceutical milestones and royalties rather than carried interest or management fees.

XtalPi internalizes wet-lab validation alongside its computational engine. Schrödinger partners with external contract research organizations for lab work; Recursion operates its own labs but targets phenotypic screening rather than physics-based crystal-structure prediction. XtalPi's Frontier Cryo-EM platform generates proprietary training data by feeding experimental protein-structure images back into the quantum-mechanics models, creating a data moat that pure software vendors cannot replicate.

The Atlanta subsidiary houses a cryo-electron microscopy lab and business-development team serving US-based pharmaceutical clients. It operates under XtalPi Inc. (US) and executes commercial contracts under the same ID4 licensing framework used in China. The Georgia location was chosen for proximity to academic cryo-EM talent and East Coast pharma headquarters (per public record).

As of its 2023 IPO disclosures, XtalPi's standard commercial agreements do not involve equity investments in partner companies. The firm's revenue model is fee-for-service with success-based milestone payments and contingent royalties. XtalPi may accept equity in lieu of cash from smaller biotech startups on a case-by-case basis, but this is not a disclosed material part of the business.

Tencent, Sequoia Capital China, and Google were early institutional backers, providing the venture funding that allowed XtalPi to scale its cloud-computing footprint on Tencent Cloud and AWS before generating meaningful pharmaceutical revenue. None of these investors hold board seats post-IPO, but their early capital effectively underwrote the firm's transition from academic project to commercial platform (per public record, 2015–2020).